Previous 10 | Next 10 |
2023-12-21 10:08:45 ET U.S. stocks on Thursday gained , with markets rebounding from their worst sell-off since late September. Wall Street in the previous session slid more than 1% after a seven-week bull run, in a decline that was chalked up to overbought territory and zero-day option...
2023-12-21 08:33:51 ET Infrared Cameras Holdings ( MSAI ) +140% . Shengfeng Development ( SFWL ) +40% . Annexon ( ANNX ) +39% stock jumps on pricing of $125M public offering of common stock. ParaZero Technologies ( PRZO ) +33% ...
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function PR Newswire STOCKHOLM , Dec. 20, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nas...
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® PR Newswire STOCKHOLM , Dec. 11, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it h...
2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome PR Newswire STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced the initiation of a Ph...
2023-11-27 18:40:01 ET Summary Q3 2023 sales for Calliditas Therapeutics' flagship drug Tarpeyo fell short of expectations but showed incremental growth. Despite challenges, the number of prescribers and improvements in market access for Tarpeyo indicate long-term success. 202...
2023-11-27 17:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-24 08:00:38 ET More on Calliditas Therapeutics Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point Calliditas stock dips as losses widen in Q3 Seeking Alpha’s Quant Rating on Calliditas Therapeutics Historica...
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy PR Newswire STOCKHOLM , Nov. 24, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...
2024-06-10 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to ...